You might be very right, but on the other hand a BP partner who took say a 20% to 30% position in the company would bring in a great deal of funding and establish a much higher trading range. While this partner would certainly be in the catbird seat when it came to buying out the company, it wouldn't be assured.
Personally I'm not pushing the idea of a buyout at all, I believe shareholders will be rewarded tremendously if we maintain independence, which can be done with a BP partner funding much of the work.
I agree with those who think a buyout under $30 billion wouldn't be acceptable, but long term I believe the company could reach a triple digit billion market cap is approval is gained for multiple solid cancers, and that's possible in under a decade.
I believe a partner recognizing the potential of the DCVax's could agree to purchase a percentage of the company based on the potential valuation now, i.e. if today they see $25 billion a fair price for the company, paying $2.5 billion for 10% would be reasonable. That should immediately bring the share price to somewhere near $20. I'm not saying it will happen, but investors would be well served if it did.
Gary
Market Data 
Markets 
AI
